Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care.

ABSTRACT:

Background

Previous experiences with non-medical switching of adalimumab (ADA) in patients with chronic inflammatory rheumatic diseases (CIRD) come mainly from phase III extension of randomised clinical trials and little from routine care.

Objectives

To analyse treatment trajectories over 2 years in patients with CIRD conducting a non-medical switch from originator to biosimilar ADA.

Design

A retrospective observational cohort study was conducted with data from a third-level rheumatology centre in Germany. CIRD patients on originator ADA who switched to ADA biosimilar from October 2018 onwards were identified and followed until September 2020.

Methods

Patients' characteristics were compared between the four a priori defined treatment trajectories 'contin

SUBMITTER: Redeker I 

PROVIDER: S-EPMC10492472 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature